CPT Code 87481: Candida nucleic acid detection billing guide

Found our content helpful?

Key takeaways

CPT Code 87481 covers infectious agent detection by nucleic acid for Candida species using an amplified probe technique.

It is the middle code of the 87480 to 87482 Candida series, and the only one that needs amplification named in the lab report.

The 2026 Medicare amount is about $19.77, paid from the Clinical Laboratory Fee Schedule rather than the physician fee schedule.

Billing 87481 when the laboratory ran a direct probe is upcoding, and it is the most common denial trigger on this code.

Pabau attaches the ICD-10 diagnosis to the lab order at the point of care, so the coding decision happens before the claim is built.

CPT Code 87481 is a billable code for infectious agent detection by nucleic acid (DNA or RNA), Candida species, amplified probe technique. A laboratory bills it when it replicates the target sequence before detecting it, most often on a molecular vaginitis panel.

The word that decides the claim is “amplified”. CPT 87480 covers the same organism by direct probe, so method is the only thing separating the two codes. If the lab report never names amplification, a payer has no basis to pay 87481.

CPT Code 87481 is maintained by the American Medical Association (AMA) under the Microbiology subsection of the Pathology and Laboratory chapter. It sits in the 87480 to 87482 Candida series, where each code represents a different analytical method and sensitivity level.

Official code description

The full AMA descriptor for 87481 is: Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique. The short descriptor used on remittance and claim forms is: Nucleic acid detect Candida amplified.

CPT 87481 vs 87480 and 87482: The amplified probe series

The 87480 to 87482 series covers one organism, Candida species, through three analytical approaches. Each code carries a different sensitivity and a different payment. Billing the wrong one is among the most cited reasons for molecular lab claim denials.

The amplified qualifier in CPT Code 87481 means the laboratory replicates the target DNA or RNA sequences before detection, most commonly by PCR.

That makes it a higher-complexity test than 87480, and the report has to document the amplification step. Without it, a payer reviewing the claim has no basis to approve 87481 over the lower-paying 87480.

The chart below turns that distinction into a check a coder can run on the report itself.

Clinical indications and specimen types for CPT 87481

CPT Code 87481 is appropriate when the clinical scenario calls for high-sensitivity detection of Candida species. A vaginitis panel workup is the most common indication, but the code applies across several patient presentations.

• Suspected vulvovaginal candidiasis: symptomatic patients with discharge, pruritus or irritation, where a wet prep is inconclusive or unavailable
• Vaginitis panel: ordered alongside 87661 (Trichomonas) or 87591 (Neisseria gonorrhoeae) as part of a multi-organism workup
• Recurrent or treatment-resistant candidiasis: empirical antifungal treatment has failed, and species confirmation now changes the therapy
• Onychomycosis evaluation: nail specimens where Candida is the suspected causative agent, per published payer LCDs including Humana’s laboratory policy
• Immunocompromised patients: transplant recipients, HIV-positive patients, or those on immunosuppressive therapy, where low-burden detection is clinically significant

Accepted specimen types include vaginal swabs, which are the most common, along with nail scrapings, skin scrapings and oral swabs. Record the specimen type in the clinical note to support medical necessity. Payer scrutiny is higher for non-vaginal specimens, so that line matters most there.

ICD-10 codes covered with CPT 87481

Correct ICD-10-CM linkage is what establishes medical necessity on a CPT 87481 claim. The diagnosis has to support running an amplification test for Candida, not merely a Candida diagnosis in general. Our ICD-10-CM codes library covers the candidiasis and vaginitis ranges in full, including the codes below.

Always check which ICD-10 codes your payer accepts under its local coverage determination for molecular vaginitis testing.

Aetna’s clinical policy bulletin CPB 0643 and BCBS Mississippi’s nucleic acid probe policy both narrow the covered diagnosis list further than the table above. The CrossCoder CPT-to-ICD-10 crosswalk tool will confirm payer-specific coverage before you submit.

Medicare reimbursement rate for CPT Code 87481

Payment for CPT 87481 comes from the Medicare Clinical Laboratory Fee Schedule (CLFS), not the physician fee schedule. That is the schedule Medicare uses for clinical laboratory tests, and it carries its own published amounts and its own lookup files.

Check the Medicare Clinical Laboratory Fee Schedule for the current year’s amount before you submit claims.

Important disclaimers: the figure above is an approximate national amount drawn from published fee schedule data, and CMS revises it.

Payment in practice also depends on your Medicare Administrative Contractor and on individual payer contracts. Cross-reference the current CLFS file before you publish a fee schedule or quote a patient estimate.

Who bills 87481, and at what rate

The CLFS pays one amount for CPT 87481 wherever the test runs. So the setting does not change the rate, and the billing question is only who performed the test and who submits the claim.

• Physician office laboratory: the practice runs the test in house and bills 87481 under the laboratory’s own NPI
• Hospital laboratory: the hospital bills the technical work, and the ordering physician does not submit 87481 separately
• Reference laboratory: the outside lab bills 87481, and the ordering provider bills only collection and handling

Private payer and Medicaid coverage

Private payer reimbursement for CPT 87481 varies widely. Aetna’s clinical policy bulletin CPB 0643 addresses vaginitis diagnosis coding including molecular tests. BCBS Mississippi publishes a nucleic acid probe identification policy that applies to this code family. Both are examples of payer-specific criteria rather than universal coverage.

Medicaid coverage is state-dependent. Some state programs cover molecular vaginitis testing on the same terms as Medicare. Others restrict coverage to culture-based methods or require prior authorization. Confirm coverage with the state program before you order a molecular panel for a Medicaid patient.

Billing and coding guidelines for CPT Code 87481

Accurate billing for CPT 87481 rests on three checks. The technique has to match the code, and the diagnosis has to support the test. Then the panel bundling rules get read before the claim drops. Most compliance failures on molecular diagnostic codes trace back to one of those three.

Common billing errors and how to avoid them

• Upcoding 87480 as 87481: billing the amplified probe code when the laboratory ran only a direct probe test is upcoding. The lab report has to state “amplified probe technique”, “NAAT” or “PCR” to support 87481. A report that says “DNA probe” with no amplification language supports 87480 instead.
• Missing ICD-10 linkage: submitting 87481 with no covered diagnosis code on the claim is a primary denial trigger. Every claim must carry at least one ICD-10-CM code that establishes medical necessity. Use the crosswalk table above as a starting reference, then verify it against your payer’s own coverage policy.
• Unbundling when a panel code applies: a multi-organism vaginitis panel that includes Candida may bundle into one panel code. Whether it does depends on the payer’s editing rules. Check the NCCI edits for 87481 before you unbundle the components.
• Failing to issue an ABN for non-covered diagnoses: check the payer’s covered ICD-10 list for 87481 first. If the diagnosis falls outside it, issue an Advance Beneficiary Notice before testing. That gives the patient the choice to proceed and pay out of pocket.
• Reference lab billing errors: when a specimen goes to a reference laboratory, only that laboratory bills 87481. The ordering physician bills the collection and handling code, such as 99000 for transport. Duplicate billing by both parties triggers automated claim edits.

Modifier 59 (distinct procedural service) may be needed when 87481 is billed alongside other nucleic acid detection codes on the same date of service.

It tells the payer the codes cover separate specimens or distinct clinical indications. Building a clean claim for this code also means reading the current NCCI edits, which change with every quarterly update.

Related CPT codes for the vaginitis panel

CPT Code 87481 is rarely ordered alone. Most molecular vaginitis workups add companion codes for other organisms, so one specimen produces several billable components. Knowing the full panel is what makes the bundling risk visible before the claim goes out.

How Pabau supports accurate billing for CPT Code 87481

A single denied CPT 87481 claim is worth about twenty dollars, which is why these denials rarely get appealed. On a practice running molecular vaginitis panels every week, they accumulate quietly.

Pabau is practice management software with claims management software built in. It catches the coding decision at the lab order rather than at the clearinghouse.

Pabau submits claims through Claim.MD, our US clearinghouse partner. For a practice ordering vaginitis panels routinely, that closes the loop between the lab order and the paid claim.

• Electronic submission to thousands of US payers, in CMS-1500 and 837P formats
• Eligibility checks before the specimen leaves the practice
• Electronic remittance advice returned into Pabau, so payments reconcile without manual entry

Pabau’s digital forms capture the clinical indication at intake, so the ICD-10 code is on the record before the claim is generated. Nobody has to reconstruct it after a denial arrives. Order sets for the panel pair each CPT code with the diagnoses that commonly support it. A high-volume practice spends less time per claim as a result.

Reduce coding errors on lab claims

Pabau attaches ICD-10 codes to lab orders at the point of care, then routes completed claims through Claim.MD for eligibility checks and electronic submission. See how it works in your practice.

Book a demo

Conclusion

CPT Code 87481 gets straightforward once the report is read before the code is chosen. Bill it only where the laboratory amplified the target, and pair it with a diagnosis the payer covers. Then check the NCCI edits whenever the code rides on a panel.

The trade-off is worth holding onto. The extra payment for the amplified code is modest, while an upcoding finding reaches back across every claim in the series. Where the report is ambiguous, coding down is the cheaper mistake.

If your practice orders molecular vaginitis panels regularly, the fix sits upstream of the claim. Book a demo to see how Pabau attaches the diagnosis to the lab order before the claim is built.

Continue your research

Need to understand denial patterns across your lab codes? Denial management in healthcare covers the most common denial triggers and how to build a systematic appeal workflow.

Billing a vaginitis panel under a hospital outpatient setting? Revenue cycle management for medical practices explains where lab codes sit in the wider claim cycle.

Want a structured reference for compliance on lab billing? Medical billing compliance outlines the documentation requirements that prevent audits on molecular diagnostic claims.

Submitting these claims electronically? The 837 file explained walks through the 837P format that carries a lab claim to the payer.

Reconciling the payment once it lands? Electronic remittance advice shows how the 835 file posts payments against the original claim.

Frequently asked questions